Dr Anchit Khanna, MD MMedSci PhD
Position:
- Peter Doherty Research Fellow, Adult Cancer Program, UNSW Medicine, UNSW, Lowy Cancer Centre
Credentials:
- Peter Doherty Research Fellow
Biography:
Dr. Anchit Khanna, is a clinician-scientist who joined the Adult Cancer Program at the Lowy Cancer Research Centre in 2012. He obtained a MD/PhD fellowship from the Academy of Finland as part of the Graduate School Program (TGPBB), University of Tampere, Finland. His projects have had translational implications and have been published in the leading journals of the field. In his first original research manuscript (Khanna et al., JNCI 2009), he identified a positive feedback loop between CIP2A and MYC, opened up opportunities to target MYC in human cancers without impacting the normal cell population. This work has been recognised globally, as evidenced by the several international awards (EACR-Young Cancer Researcher Award, CELL Press Special Commendation Award) that Dr Khanna has received for this work. In his other major project, Dr. Khanna delineated a mechanism by which constitutive DNA-damage promotes cancer growth. These findings, also holding significant translational relevance, have captured the attention of both the academia and the industry. The Scientist of the Year (2011) Award-Finland and the AACR-GlaxoSmithKline Outstanding Clinical Scholar Award at the annual AACR meeting in Orlando, USA, and special highlight by Nature-SciBX are a testimony to this. His pioneering work has resulted in invitations to write comprehensive review on CIP2A and DNA-damage for Cancer Research, the most cited cancer research journal. Lately, he received the new investigator NHMRC-project grant (role CIA), the NHMRC-Peter-Doherty early career fellowship and the ComBio 2014 young investigator award for executing his ideas on combatting solid tumours, especially prostate and glioblastoma.
Best publications:
1. Khanna A, Bockelman C, Hemmes A, Junttila MR, Wiksten JP, Lundin M, Junnila S, Murphy DJ, Evan GI, Haglund C, Westermarck J and Ristimaki A. MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J Natl Cancer Inst. 2009; 101(11):793-805.
2. Khanna A, Okkeri J, Bilgen T, Tiirikka T, Vihinen M, Visakorpi T and Westermarck J. ETS1 mediates MEK1/2-dependent overexpression of cancerous inhibitor of protein phosphatase 2A (CIP2A) in human cancer cells. PLoS One. 2011; 6(3):e17979
3. Khanna A, Kauko O, Bockelman C, Laine A, Schreck I, Partanen JI, Szwajda A, Bormann S, Bilgen T, Helenius M, Pokharel YR, Pimanda J, Russel MR, Haglund C, Cole KA, Klefstrom J, et al. Chk1 targeting reactivates PP2A tumor suppressor activity in cancer cells. Cancer Res. 2013; 73(22):6757-6769.
4. Khanna A *, Pimanda JE and Westermarck J *. Cancerous Inhibitor of Protein Phosphatase 2A, an Emerging Human Oncoprotein and a Potential Cancer Therapy Target. Cancer Res. 2013 Nov 15;73(22):6548-53.
5. Khanna A*, Patil R and Deshmukh A. Assessment of the potential of pathological stains in human prostate cancer. J Clin Diagn Res. 2014; 8(1):124-128.
6. Khanna A* and Pimanda JE. Clinical significance of Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A) in human cancers. Int. J Cancer. 2015 Jan 13. doi: 10.1002/ijc.29431.
7. Khanna A*., Rane JK., Kivinummi KK., Urbanucci A., Helenius MA., Tolonen TT., Saramäki OR., Latonen L., Manni V., Pimanda JE., Maitland NJ., Westermarck J., Visakorpi T *. CIP2A is a candidate therapeutic target in clinically challenging prostate cancer cell populations. Oncotarget. 2015 Apr 19.
8. Khanna A*. DNA Damage in Cancer Therapeutics: A Boon or a curse? Cancer Res. 2015 Jun 1;75(11):2133-2138.
( * corresponding author )
Work Focus:
- Work Focus (Biomedical): Prostate Cancer, Androgen Receptor, Drug Resistance, CRPCs
Prostate Cancer, Glioblastoma, , .
